

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

DEC 17 2001

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Application Number	09/922,631
Filing Date	August 6, 2001
First Named Inventor	Richard Apodaca et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ORT-1473

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
KA		ALBENGRES, E. et al.; "Systemic Antifungal Agents"; Drug Safety; Feb. 1998; 18(2):83-97	
KA		ALI, S.M. et al.; "Design, Synthesis, and Structure-Activity Relationships of Acetylene-Based Histamine H3 Receptor Antagonists"; J. Med. Chem.; 1999 42:903-909	
KA		ARRANG, J.M. et al.; "Auto-inhibition of brain histamine release mediated by a novel class (h3) of histamine receptor" Nature; April 1983; 302:832-837	
KA		ASH, A.S.F. et al.; "Receptors Mediating Some Actions of Histamine"; Br. J. Pharmac. Chemother.; 1966 27:427-439	
KA		BACK, D.J.; et al.; "Inhibition of tolbutamide metabolism by substituted imidazole drugs in vivo:evidence for a structure-activity relationship"; Br. J. Pharmacol.; 1985 85:121-126	
KA		BARNES, J.C. et al.; "The selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release in vivo"; Soc. Neurosci. Abstr.; 1993 19:1813	
KA		BLACK, J.W. et al.; "Definition and Antagonism of Histamine H2-receptors"; Nature; April 1972; 236:385-390	
KA		GARBAG, M. et al.; "S-[2-(4-Imidazolyl)ethyl]isothiurea, a Highly Specific and Potent Histamine H3 Receptor Agonist"; J. Pharmacol. Exp. Ther.; 1992; 263(1):304-310	
KA		GILATECH, INC.; "Other News To Note"; Bioworld Today, March 2, 1999, page 3	
KA		GILATECH, INC.; "Gilatech's first drug candidate begins phase I human clinical trials"; Gilatech Inc. Press Release; November 5, 1998	
KA		ICHINOSE, M. et al.; "Histamine H3-receptors modulate nonadrenergic noncholinergic neural bronchoconstriction in guinea-pig in vivo"; P.J. Eur. J. Pharmacol; 1989; 174:49-55	
KA		IMAMURA, M. et al.; "Unmasking of Activated Histamine H3-Receptors in Myocardial Ischemia: Their Role as Regulators of Exocytotic Norepinephrine Release 1,2"; J. Pharmacol. Exp. Ther.; 1994; 271(3):1259-1266	
KA		KAPETANOVIC, I.M. et al.; "Nafimidone, An Imidazole Anticonvulsant, and its Metabolite as Potent Inhibitors of Microsomal Metabolism of Phenytoin and Carbamazepine"; H. J. Drug Metab. Dispos.; 1984 12(5):560-564	
KA		KORTE, A. et al.; "Characterization and Tissue Distribution of H3 Histamine Receptors in Guinea Pigs by Na-Methylhistamine"; Biochem. Biophys. Res. Commun.; May 1990; 168(3):979-986	
KA		KRAUSE, M. et al.; "The Histamine H3 Receptor-A Target for New Drugs"; Leurs, R.; Timmerman, H. (Eds.); Elsevier; 1998; 175-196	
KA		PHILLIPS, J. G. et al.; "The Histamine H3 Receptor-A Target for New Drugs"; Leurs, R.; Timmerman, H. (Eds.); Elsevier; 1998; 197-222	
KA		LAVRIJSEN, K. et al.; "Induction Potential of Antifungals Containing an Imidazole or Triazole Moiety"; Biochem. Pharmacol.; 1986 35(11):1867-1878	
KA		LEURS, R. et al.; "The medicinal chemistry and therapeutic potentials of ligands of the histamine h3 receptor" Prog. Drug. Res.; 1995; 45:107-165	
KA		LIN, Jian-Sheng et al. "Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat"; Brain Res.; 1990; 523:325-330	
KA		LINNEY, I.D. et al.; "Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H3 Receptor Antagonists"; J. Med. Chem.; 2000; 43:2362-2370	
KA		LOVENBERG, T.W. et al.; "Cloning and Functional Expression of the Human Histamine H3 Receptor"; Mol. Pharmacol; 1999 55:1101-1107	
KA		MACHIDORI, H. et al.; "Zucker obese rats: defect in brain histamine control of feeding"; Brain Res.; 1992; 590:180-186	
KA		MCLEOD, R.L. et al.; "Antimigraine and Sedative Activity of SCH 50971: A Novel Orally-Active Histamine H3 Receptor Agonist"; Soc. Neurosci. Abstr.; 1996; 22:2010	
KA		MONTI, J.M. et al.; "Effects of selective activation or blockade of the histamine h3 receptor on sleep and wakefulness"; Eur. J. Pharmacol.; 1991; 205:283-287	
KA		MORISSET, S. et al.; "High constitutive activity of native H3 receptors regulates histamine neurons in brain"; Nature; Dec., 2000; 408:860-864	
KA		ODA, Tamaki et al.; "Molecular Cloning and characterization of a Novel Type of Histamine Receptor Preferentially Expressed In Leukocytes"; J. Biol. Chem.; Nov. 2000; 275(47):36781-36786	
KA		PANULA, P. et al.; "Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease" Soc. Neurosci. Abstr.; 1995; 21:1977	
KA		ROULEAU, A. et al.; "Bioavailability, Antinociceptive and Antiinflammatory Properties of BP 2-94, a Histamine H3 Receptor Agonist Prodrug"; J. Pharmacol. Exp. Ther.; 1997 281(3):1085-1094	

Examiner Signature	Kamal Saeed	Date Considered	03/11/2002
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

PE JC169
 DEC 10 2001
 PATENT & TRADEMARK OFFICE

TECH CENTER PTO/SB/08A (08-00)
use through 10/31/2002 OMB 065-1003 2900

Approved for use through 10/31/2002 OMB 0451-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	09/922,631
Filing Date	August 6, 2001
First Named Inventor	Richard Apodaca et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ORT-1473

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature	Kamal Saeed	Date Considered	03/11/2002
-----------------------	-------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 095-1003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.